DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Conditions:   HER2 Breast Cancer;   Non-small Cell Lung Carcinoma Interventions:   Drug: Trastuzumab deruxtecan (DS-8201a);   Drug: Pembrolizumab Sponsors:   Daiichi Sankyo, Inc.;   AstraZeneca UK Limited;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials